Top 8 Companies of the Global Injection Pen Market 2025

The global injection pen market was valued at USD 37.80 billion in 2024. The market is expected to grow at a CAGR of 7.20% during the forecast period of 2025-2034, with the values likely to reach USD 75.76 billion by 2034. The market is driven by the rising prevalence of chronic diseases requiring frequent drug administration and technological advancements in injection pen design and functionality.

An injection pen is a medical device designed for the convenient and precise administration of injectable medications. It combines a prefilled cartridge and a user-friendly mechanism, enabling self-administration with minimal training. Commonly used for conditions like diabetes, hormone therapy, and autoimmune diseases, injection pens enhance patient compliance, safety, and comfort. Their portability and ease of use make them a preferred alternative to traditional syringes.

The global injection pen market is experiencing significant growth, driven by the increasing prevalence of chronic disease and the rising demand for self-administered therapies. The adoption of injection pens is further accelerated by technological innovations and intuitive designs. Additionally, increasing healthcare awareness and the shift toward home-based care are key factors driving the continued expansion of this market. Leading manufacturers are investing in innovation and product development, focusing on patient convenience, safety features, and digital connectivity to maintain competitiveness and meet evolving consumer needs.

In May 2024, the launch of Metoject subcutaneous injection pen by Eisai Co., Ltd. and Nippon Medac Co., Ltd. in Japan marked the introduction of the country's first self-administerable methotrexate pen-type autoinjector. This advancement drives the injection pen market by enhancing patient convenience, safety, and self-injection adherence.

Let’s explore the profile of top companies leading the global injection pen market in 2025

1.    Becton, Dickinson and Company

BD (Becton, Dickinson and Company) plays a vital role in the injection pen market with its BD Physioject disposable autoinjector 1 mL. Designed for biologic delivery in chronic disease management, this device offers ease of use, dose accuracy, and enhanced safety features. With over a decade of presence in the market, the BD Physioject reflects the company’s commitment to innovation and improving patient outcomes, reinforcing BD’s contribution to the continued growth of the injection pen market.

2.    Eli Lilly and Company

Eli Lilly and Company is a leading pharmaceutical firm actively engaged in the injection pen market through its comprehensive diabetes care portfolio. The company offers various insulin therapies delivered via its KwikPen injection system, including insulin lispro injection U-100 and insulin lispro protamine mix 75/25. Lilly’s efforts to provide affordable insulin through both branded and non-branded options have strengthened its market presence and supported global demand for self-administered injectable treatments.

3.    Ypsomed AG

Ypsomed AG is a major developer and manufacturer of injection and infusion systems. The company provides advanced autoinjector solutions, including the YpsoMate range, such as YpsoMate 2.25 for large volume injections and YpsoMate 5.5 for higher dose requirements. Ypsomed’s SmartPilot and YpsoMate On incorporate digital features to support personalized medicine, enhancing patient engagement and adherence. These innovations not only improve treatment outcomes but also reinforce Ypsomed’s position in the injection device market.

4.    Biocon Biologics Limited

Biocon Biologics is a key player in the global injection pen market, with a robust portfolio of cost-effective biosimilar insulins. Its insulin glargine injection pen, Semglee, was the first interchangeable biosimilar approved under the U.S. FDA’s 351(k) pathway. The company supports global diabetes care by donating injection pens and expanding insulin access in underserved regions, strengthening its position in market growth and humanitarian outreach.

5.    Pfizer Inc.

Pfizer Inc., headquartered in New York, is a leading global biopharmaceutical company actively contributing to the injection pen market. In October 2024, the United States Food and Drug Administration approved Hympavzi (marstacimab -hncq), a once-weekly, subcutaneous hemophilia treatment administered via a prefilled auto-injector pen. This innovation enhances Pfizer’s position in the market by addressing unmet needs in hemophilia care and supporting growth in injectable drug delivery solutions.

6.    Novartis AG

Novartis AG, a global player in pharmaceuticals, plays a significant role in the injection pen market with its Sensoready Pen, used to deliver Cosentyx (secukinumab ). Designed for ease of use and patient comfort, the pen supports treatment for autoimmune diseases. Novartis strengthens its market presence by promoting self-administration, improving patient experience, and contributing to the broader adoption of injection pen technologies worldwide.

7.    Novo Nordisk A/S

Novo Nordisk stands as a leader in diabetes care, offering advanced drug delivery systems. Its NovoFine needle portfolio, available in various lengths and widths, is crafted to reduce injection pain and lower the risk of intramuscular delivery. These needles are compatible with most pen devices, simplifying use. Through innovations like the NovoPen 6 and NovoPen Echo Plus, Novo Nordisk continues to drive growth in the insulin pen market.

8.    Merck KGaA

Merck offers a range of rhGH delivery devices under the Saizen brand, including manual injection pens, smart pens, and auto-injectors. These devices cater to diverse patient needs, offering convenience, flexibility, and valuable insights for healthcare providers. Notable products include the Aluetta mechanical pen, Aluetta with Smartdot, and the Easypod auto-injector. These devices enhance patient engagement and adherence, contributing to the global growth of the injection pen market.